Primary Peptides Inc.
Primary Peptides is a clinical stage company focused on creating new therapeutics through protein manipulation. Our initial focus areas are Cardiovascular Disease, Oncology and Neurodegeneration.
Our science and technology are rooted in our deep and extensive knowledge of neuroscience and proteome informatics. By combining these with our computational strategies, we have developed two innovative platform technologies that enable us to design therapeutic interventions by manipulating how proteins interact and are degraded in ways that are not amenable using small molecules and antibodies.
Our innovative discovery platform technologies are:
1) Protein-protein interaction blockade. Using novel computational strategies and proteome informatics, we can precisely identify and block the interactions of two disease-causing proteins to inhibit disease progression.
2) Protein degradation. We harness the body's own natural processes to destroy disease causing proteins. Through our proprietary Chaperone-mediated Autophagy Protein Degradation Technology (CHAPTAC), we reversibly degrade disease proteins via the lysosome or the proteasome degradation machineries of the cell. Our CHAPTAC technology overcomes the current limitations of existing protein degradation techniques. We reversibly degrade proteins. CHAPTAC is more versatile than PROTAC in cases where the proteasome is dysfunctional. Since our peptides are made of natural amino acids, they are degraded together with the target protein, and consequently have less toxicity compared with thalidomide-based PROTAC methods of targeted protein degradation.
Our technologies are enabling us to expand the scope of new targets for drug development, by unlocking the untapped pool of undruggable targets. Our goal is to develop a new generation of therapeutics for patients worldwide, who currently have few options, if any, to treat their diseases safely and effectively.
- Cardiovascular Disease
- Drug Discovery
- Neurological Diseases
We are looking For:
Seeking partnering collaborations involving our technologies and assets. Please contact: Julie P Rezler Vice President Corporate Development email@example.com